In this trial of patients with recurrent Cdiff, they were treated with vancomycin, then randomized to no further therapy, duodenal lavage, or duodenal infusion of donor feces. Those in the donor feces group had 81% resolution of disease at 10 weeks (after 1 infusion), compared to 23% of those in the lavage group, and 31% of the vancomycin only group, with no difference in adverse events. This will become the new standard of care for recurrent Cdiff (abstract).
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.